Business Description
Healios KK
ISIN : JP3835100003
Total Employee Number:
102Description
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.2 | |||||
Equity-to-Asset | 0.32 | |||||
Debt-to-Equity | 0.34 | |||||
Debt-to-EBITDA | -1.31 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 1.1 | |||||
Beneish M-Score | 19.85 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -10 | |||||
3-Year EBITDA Growth Rate | 38.3 | |||||
3-Year EPS without NRI Growth Rate | 33.6 | |||||
3-Year FCF Growth Rate | 24.4 | |||||
3-Year Book Growth Rate | -15.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 300.23 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 0.03 | |||||
9-Day RSI | 0.9 | |||||
14-Day RSI | 4.71 | |||||
3-1 Month Momentum % | -33.33 | |||||
6-1 Month Momentum % | -6.74 | |||||
12-1 Month Momentum % | -43.22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.05 | |||||
Quick Ratio | 2.05 | |||||
Cash Ratio | 1.88 | |||||
Days Sales Outstanding | 1058.5 | |||||
Days Payable | 526.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -22.3 | |||||
Shareholder Yield % | -23.7 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -155.41 | |||||
Operating Margin % | -5035.14 | |||||
Net Margin % | -4233.78 | |||||
EBITDA Margin % | -2679.73 | |||||
FCF Margin % | -5171.63 | |||||
OCF Margin % | -4916.53 | |||||
ROE % | -84.3 | |||||
ROA % | -17.33 | |||||
ROIC % | -24.33 | |||||
3-Year ROIIC % | 49.91 | |||||
ROC (Joel Greenblatt) % | -232.08 | |||||
ROCE % | -17.52 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 352.94 | |||||
PB Ratio | 4.4 | |||||
Price-to-Tangible-Book | 10.59 | |||||
EV-to-EBIT | -11.04 | |||||
EV-to-EBITDA | -12.59 | |||||
EV-to-Revenue | 337.3 | |||||
EV-to-FCF | -6.46 | |||||
Price-to-GF-Value | 4.29 | |||||
Earnings Yield (Greenblatt) % | -9.06 | |||||
FCF Yield % | -11.64 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:HLOSF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Healios KK Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.49 | ||
| EPS (TTM) ($) | -0.181 | ||
| Beta | -0.6133 | ||
| 3-Year Sharpe Ratio | 0.15 | ||
| 3-Year Sortino Ratio | 0.28 | ||
| Volatility % | 58.22 | ||
| 14-Day RSI | 4.71 | ||
| 14-Day ATR ($) | 0.006373 | ||
| 20-Day SMA ($) | 1.8 | ||
| 12-1 Month Momentum % | -43.22 | ||
| 52-Week Range ($) | 1.8 - 4.45 | ||
| Shares Outstanding (Mil) | 135 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Healios KK Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Healios KK Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Healios KK Frequently Asked Questions
What is Healios KK(HLOSF)'s stock price today?
The current price of HLOSF is $1.80. The 52 week high of HLOSF is $4.45 and 52 week low is $1.80.
When is next earnings date of Healios KK(HLOSF)?
The next earnings date of Healios KK(HLOSF) is .
Does Healios KK(HLOSF) pay dividends? If so, how much?
Healios KK(HLOSF) does not pay dividend.
Guru Commentaries on OTCPK:HLOSF
No articles.
Press Release
Articles on Healios KK
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers